Stocktoria
Roivant Sciences Ltd. ROIV
Roivant Sciences Ltd. financials (annual)
Bars are annual figures from 2021 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M | $23.8M |
| R&D expense | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M | $236.6M |
| SG&A expense | — | — | $687.4M | $600.5M | $775.0M | — |
| Operating income | -$515.1M | -$1.0B | $4.5B | -$906.8M | -$1.4B | -$1.1B |
| Interest expense | — | — | $34.8M | $28.0M | $7.0M | $2.8M |
| Income tax | $133.3M | $48.2M | $21.5M | $4.1M | $369,000 | $1.7M |
| Net income | -$299.8M | -$172.0M | $4.3B | -$1.0B | -$845.3M | -$809.2M |
| EPS (diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 | — |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M | -$552.1M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M | -$557.9M |
| Cash & equivalents | $1.4B | $2.7B | $6.5B | $1.7B | $2.1B | $2.1B |
| Inventory | — | — | $35.3M | $2.8M | $0 | — |
| Total assets | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B | $2.6B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M | $527.7M |
| Shareholders' equity | $5.3B | $5.2B | $6.4B | $1.6B | $2.0B | $2.0B |
Growth · year-over-year · Revenue CAGR -19.1%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue growth | -71.6% | -11.2% | +3.8% | -43.0% | +132.3% | — |
| Net income growth | — | -104.0% | — | — | — | — |
| EPS growth | — | -104.6% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.